USOO8957025B2 (12) United States Patent (10) Patent N0.: US 8,957,025 B2 Owen (45) Date of Patent: Feb. 17, 2015 (54) ENKEPHALIN ANALOGUES OTHER PUBLICATIONS (75) Inventor: Dafydd Rhys Owen, Cambridge, MA Waldhoer, et al., “Opioid Receptors”, Annu. Rev. Biochem., vol. 73, (Us) pp. 953-990 (2004). Bileviciute-Ljungar, et al., “Peripherally Mediated Antinociception (73) Assignee: P?zer Inc., New York, NY (US) of the p-Opioid Receptor Agonist 2-[(4,501-Epoxy-3-hydroxy-14B methoxy- 1 7-methylmorphinan-6B-yl)amino]acetic Acid (HS-731) (*) Notice: Subject to any disclaimer, the term of this after Subcutaneous and Oral Administration in rats With Car patent is extended or adjusted under 35 rageenan-Induced Hindpaw In?ammation”, JPET, vol. 317(1), pp. U.S.C. 154(b) by 0 days. 220-227 (2006). Gordon, et al., “Activation of P-glycoprotein ef?uX transport amelio (21) Appl. No.: 14/125,690 rates opioid CNS effects Without diminishing analgesia”, Drug Dis covery Today: Therapeutic Strategies, vol. 6(3), pp. 97-103 (2009). (22) PCT Filed: Jun. 29, 2012 He, et al., “Methadone Antinociception is Dependent on Peripheral Opioid Receptors”, Journal of Pain, vol. 10(4), pp. 369-379 (2009). (86) PCT No.: PCT/IB2012/053327 Koppert, et al., Peripheral Antihyperalgesic Effect of Morphine to Heat, but Not Mechanical, Stimulation in Healthy Volunteers after § 371 (00)’ Ultraviolet-B Irradiation, Anesthesia & Analgesia, vol. 88(1), pp. (2), (4) Date: Dec. 12, 2013 117-122 (1999). Oeltjenbruns, et al., “Peripheral Opioid Analgesia: Clinical Applica (87) PCT Pub. No.: WO2013/008123 tions”, Current Pain and Headache Reports, vol. 9(1), pp. 36-44 PCT Pub. Date: Jan. 17, 2013 (2005). Stein, et al., “Attacking pain at its source: new perspective on opioids”, Nature Medicine, vol. 9(8), pp. 1003-1008 (2003). (65) Prior Publication Data Stein, et al., “Peripheral mechanisms of opioid analgesia”, Current US 2014/0121279 A1 May 1, 2014 Opinion in Pharmacology, vol. 9(1), pp. 3-8 (2009). Wenk, et al., “Morphine Directly Inhibits Nociceptors in In?amed Skin”, Journal of Neurophisiologyvol. 95(4), pp. 2083 -2097 (2006). Related US. Application Data Osterlund Modalen, et al., A Novel Molecule (Frakefamide) With Peripheral Opioid Properties: The Effects on Resting Ventilation (60) Provisional application No. 61/507,280, ?led on Jul. Compaired With Morphine and Placebo, Anesthesia & Analgesia, 13, 2011. vol. 100, pp. 713-717 (2005). DeHaven-Hudkins, et al., “Pherpherally Restricted Opioid Agonists Int. Cl. as Novel Analgesic Agents”, Current Pharmaceutical Design, vol. (51) 10(7), pp. 743-757 (2004). A61P 25/04 (2006.01) KapitZke, et al., “Endogenous opioid analgesia in peripheral tissues C07C 23 7/06 (2006.01) and the clinical implications for pain control”, Therapeutics and A61K 38/06 (2006.01) Clinical Risk Management, vol. 1(4), pp. 279-297 (2005). C07K 5/065 (2006.01) Koda, et al., “Comparison of the in vitro apparent permeability and A61K 31/165 (2006.01) stability of opioid mimetic compounds With that of the native A61K 38/00 (2006.01) peptide”, Bioorganic & Medicinal Chemistry Letters, vol. 17(7), pp. (52) US. Cl. 2043-2046 (2007). CPC ............. .. C07C 237/06 (2013.01); A61K38/06 (Continued) (2013.01); C07K 5/06078 (2013.01); A61K 31/165 (2013.01); A61K 38/00 (2013.01) Primary Examiner * Maury Audet USPC ....... .. 514/18.4; 514/185; 514/21.9; 530/331 Assistant Examiner * Fred Reynolds (58) Field of Classi?cation Search (74) Attorney, Agent, or Firm * A. Dean Olson None See application ?le for complete search history. (57) ABSTRACT (56) References Cited The present invention relates to dipeptide enkephalin ana logues of Formula (I) and their tautomers, ionic forms and U.S. PATENT DOCUMENTS pharmaceutically acceptable salts, and their use in medicine, in particular as opioid agonists. 6,114,310 A 9/2000 Chamberland et al. 2011/0207654 A1* 8/2011 Barber et al. ................ .. 514/1.1 FOREIGN PATENT DOCUMENTS 0154234 9/1985 91/11172 8/1991 94/02518 2/1994 98/55148 12/1998 2008/047229 4/2008 CH3 0 CH3 NH2 2008/118758 10/2008 2008/135826 11/2008 2009/012242 1/2009 2010/079443 7/2010 2011104649 9/2011 5 Claims, No Drawings US 8,957,025 B2 Page 2 (56) References Cited Castiglione-Morelli, et al., “A 500-MHz Proton Nuclear Magnetic Resonance Study of u Opioid Peptides in a Simulated Receptor OTHER PUBLICATIONS Environment”, J. Med. Chem., vol. 30(11), pp. 2067-2073 (1987). Guerrini, et al., “Opioid receptor selectivity alteration by single resi Hardy, et al., “Peripherally Acting Enkephalin Analogues. 1. Polar due replacement: synthesis and activity pro?le of [Dmtl]deltorphin Pentapeptides”, J. Med. Chem., vol. 31(5), pp. 960-966 (1988). B”, Eur. J. Pharmacol., vol. 302(1-3), pp. 37-42 (1996). Hardy, et al., “Peripherally Acting Enkephalin Analogues. 2. Polar Schiller, et al., “Synthesis and in vitro opioid activity pro?les of Tri- and Tetrapeptides”, J. Med. Chem., vol. 32 (5), pp. 1108-1118 DALDA analogues”, Eur. J. Med. Chem., vol. 35(10), pp. 895-901 (1989). (2000). Kharkevich, et al., “Opioid ligands with extraordinarily high u-se Szeto, et al., “In Vivo Pharmacokinetics of Selective u-Opioid lectivity: dermorphin tetrapeptides containing thymine-modi?ed Peptide Agonists”, JPET, vol. 298(1), pp. 57-61 (2001). alanine residues”, FEBS Letters, vol. 351(3), pp. 308-310 (1994). Bajusz, et al., “Further Enhancement of Analgesic Activity: Salvino, et al., “Structure Activity Relationships of Non-Peptide Enkephalin Analogs With Terminal Guanidino Group”, FEBS Let Bradykinin B2 Receptor Antagonists”, Bioorganic & Medicinal ters, vol. 110(1), pp. 85-87 (1980). Chemistry Letters, vol. 5(4), pp. 357-362 (1995). Ogawa, et al., Peptide Science , vol. 69(2), pp. 101-104 (2001). Dankwardt, et al., “Nonpeptide Bradykinin Antagonist Analogs Konopinska, et al., “Proctolin and its Analogues. Structure/Biologi Based on a Model of a Sterling-Winthrop Nonpeptide Bradykinin cal Function Relationship Studies”, Polish J. Chem, vol. 68(7), pp. Antagonist Overlapped with Cyclic Hexapeptide Bradykinin 1437-1439 (1994). Antagonist Peptides”, Bioorganic & Medicinal Chemistry Letters, Fanciulli et al., “Effect of exogenous growth hormone administration vol. 7(14), pp. 1921-1926 (1997). on endogenous growth hormone secretion induced by a met Ogawa, et al., “Structure-Activity Relationships (SAR) of enkephaline analog”, Eur. J. Endocrinology, vol. 134, 73-76 (1996). [D-Arg2]Dermorphin(1-4)Analogues, Na-Amidino-Tyr-D-Arg Giusti, et al., “The effect of a met-enkephalin analogue on growth hormone, prolactin, gonadotropins, cortisol and thyroid stimulating Phe-Xl”, Chem. Pharm. Bull., vol. 50(6), pp. 771-780 (2002). hormone in healthy elderly men”, Acta Endocrinologica, vol. 127, Ogawa, et al., Synthesys and Structure-Activity Relationships of an Orally Available and Long-Acting Analgesic Peptide, Na-Amidino pp. 205-209 (1992). Howlett, et al., “:ack of Modulation of the Adrenocortical Response Tyr-D-Arg-Phe-MeBAla-OH (ADAMB), J. Med. Chem., vol. to ACTH by an Opioid Peptide”, Horm. Metab. Res., vol. 23, pp. 45(23), pp. 5081-5089 (2002). 341-343 (1991). Genco, et al., “Antimicrobial activity of magainin analogues against Konopinska, et al., “Role of guanidine group at the N-terminal anaerobic oral pathogens”, International Journal of Antimicrobial proctolin chain in cardioexcitatory effects in insects”, Int. J. Peptide Agents, vol. 21(1), pp. 75-78 (2003). Protein Res., vol. 35, pp. 12-16 (1990). Deguchi, et al., “Blood-Brain Barrier Permeability of Novel Delitala, et al., “Opioids Stimulate Growth Hormone (GH) Release in [D-Arg2]Dermorphin (1-4)Analogs Transport Property is Related to Man Independently of GH-Releasing Hormone”, J. Clin. Endocri the Slow Onset of Antinociceptive Activity in the Central Nervous nology and Metab., vol. 69(2), pp. 356-358 (1989). System”, JPET, vol. 310(1), pp. 177-184 (2004). Borges, et al., “Opioid peptides do not modulate atrial natriuretic Wolin, et al., “Novel glycine transporter type-2 reuptake inhibitors. peptide or aldosterone release under basal conditions in man”, Jour Part 1: 01-amino acid derivatives”, Biorganic & Medicinal Chemistry, nal ofEndocrinology, vol. 116, pp. 313-317 (1988). vol. 12(16), pp. 4477-4492 (2004). Marastoni, et al., “Opioid peptides. Biological Study of [D-Met02] Liu, et al., “Utilization of Combined chemical Modi?cations to Dermorphin Analogues in Relation to the Plurality of Opioid Recep Enhance the Blood-Brain Barrier Permeability and Pharmacological tors XI”, 11 Farmaco, vol. 42, pp. 125-131 (1987). Activity of Endomorphin-l”, JPET vol. 319(1), pp. 308-316 (2006). Salvadori, et al., “Synthetic Tetrapeptides Related to Dermorphin: Gentilucci, et al., “Antiangiogenic Effect of Dual/ Selective (1551/ Potent Long Lasting Analgesic Action Following Subcutaneous 0153 Integrin Antagonists Designed on Partially Modi?ed Retro Administration” Peptides, vol. 6(3), pp. 127-129 (1985). Cervinin, et al., “Antinociceptive and Other Opioid Effects of a New Inverso Cyclotetrapeptide Mimetics”, J. Med. Chem., vol. 53(1), pp. Series of Dermorphin Analogues After Subcutaneous Administration 106-118 (2010). in the Ra ”, Peptides, vol. 6, pp. 433-437 (1985). Suhs, et al., “Synthesis of Functionalized Guanidino Amino Acids”, Salvadori,et al., “Synthesis and Opioid Activity of Chemistry: A European Journal, vol. 12(31), pp. 8150-8157 (2006). [Sar4]Dermorphin-Tetrapeptide analogues”, Hoppe-Seyler’s Z. Mizoguchi, et al., “Involvement of endogenous opioid peptides in the Physiol. Chem., vol. 365, pp. 1199-1206 (1984). antinociception induced by the novel dermorphin tetrapeptide analog Castiglione, “Structure-Activity Relationships in Dermorphin-Like amidino-TAPA”, European Journal of Pharmacology, vol. 560(2-3), Peptides”, Highlights in Receptor Chemistry, 1984, Elsevier, pp. pp. 150-159 (2007). 149-168. Liu, et al., “Differential cardiovascular effects of synthetic peptides Salvadori, et al., “Synthesis and pharmacological activity of derived from endomorphin-l in anesthetized rats”, Peptides, vol. dermorphin tetrapeptide-analogs”, Eur. J. Med. Chem.-Chim. Ther, 29(6), pp. 1048-1056 (2008).